Hoth Therapeutics Inc., a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, has deployed the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers.

The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of KIT-driven pathways, and preparation of regulatory documentation ahead of IND submission.

HT-KIT has received Orphan Drug Designation and is designed to address cancers driven by KIT mutations, an area of significant unmet medical need. It is advancing toward Investigational New Drug (IND) submission and Phase 1 clinical evaluation.

“Hoth’s integration of OpenAI’s API supports execution of our IND-enabling strategy for HT-KIT as we advance toward Phase 1,” said Robb Knie, Chief Executive Officer, Hoth Therapeutics.

More Hoth News

Hoth recently filed two U.S. provisional patent applications that significantly expand its intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.